|Articles|August 25, 2022
Genetic insights for biopharmaceuticals: Propelling drug candidates into therapeutic assets
Author(s)Thermo Fisher
For biopharmaceutical developers, optimizing R&D investment in new technologies is an essential way to gain and sustain a competitive edge. Clinical trials present a tremendous opportunity to leverage advanced genetics technologies and practices to improve efficiency and reduce costs.
Trending on PharmExec
1
Eli Lilly and Novo Nordisk Shift Patients From Compounded Drugs to Lower-Cost Weight-Loss Pills: Report
2
FDA Approves Datroway for Patients with Metastatic Triple-Negative Breast Cancer Who Are Not PD-1/PD-L1 Inhibitor Candidates
3
The Evolving Relationship Between FDA and Biotech
4
Eli Lilly Enters $202 Million Agreement to Acquire Engage Bio
5